Effects of small molecular inhibitors on the binding between HIV-1 reverse transcriptase and DNA as revealed by SPR biosensor

Abstract Surface plasmon resonance (SPR) biosensor technique was applied to analyze the human immunodeficiency virus 1 reverse transcriptase (HIV-1 RT) binding to DNA template–primer (T–P) duplexes. The kinetics including the initial binding and the subsequent conformation change of the protein–DNA complex in the absence and presence of various chemicals were determined. The effects of three nucleoside-based reverse transcriptase inhibitors (NRTIs) and three non-nucleoside-based reverse transcriptase inhibitors (NNRTIs) on the RT–DNA interaction were analyzed based on the conformation change model. Efavirenz (EFV) slightly affected the binding kinetics of the RT–DNA interaction and the binding affinity ( K A  = 2.99 × 10 8  M −1 ) is lower than that in the absence of the inhibitor ( K A  = 5.61 × 10 8  M −1 ). Nevirapine (NVP) induced RT to bind tightly to DNA duplexes followed by a conformation change step. The action of an unsaturated fatty acid, nervonic acid (NA) was similar to NVP. The dideoxynucleosides, whether complementary (‘correct’) or non-complementary (‘incorrect’) to the bases of 3′-end of template–primer DNA, showed no effect on the binding of RT to DNA. However, the initial association and dissociation rates for the RT–DNA interaction are greater in the presence of ‘correct’ dideoxynucleosides than that of in the presence ‘incorrect’ ones, indicating slight preference of RT to ‘correct’ bases. The azido group of AZT (3′-azido-3′-deoxythymidine) enhanced the dissociation of RT from DNA in the initial binding step, where the absence of which resulted in a 34-fold increase in the overall binding affinity ( K A  = 1.94 × 10 10  M −1 ).

[1]  D. Stuart,et al.  High resolution structures of HIV-1 RT from four RT-inhibitor complexes. , 1996 .

[2]  J. Culp,et al.  Kinetic and mutational analysis of human immunodeficiency virus type 1 reverse transcriptase inhibition by inophyllums, a novel class of non-nucleoside inhibitors. , 1994, The Journal of biological chemistry.

[3]  E. Middleton,et al.  The effects of plant flavonoids on mammalian cells: implications for inflammation, heart disease, and cancer. , 2000, Pharmacological reviews.

[4]  N. Sluis-Cremer,et al.  Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. , 2002, European journal of biochemistry.

[5]  M. Ciolkowski,et al.  A surface plasmon resonance method for detecting multiple modes of DNA-ligand interactions. , 2000, Journal of pharmaceutical and biomedical analysis.

[6]  J. Papadimitriou,et al.  A critical analysis of the pharmacology of AZT and its use in AIDS. , 1999, Current medical research and opinion.

[7]  J. Hsieh,et al.  Kinetic mechanism of the DNA-dependent DNA polymerase activity of human immunodeficiency virus reverse transcriptase. , 1993, The Journal of biological chemistry.

[8]  A. D. Clark,et al.  Crystal structure of human immunodeficiency virus type 1 reverse transcriptase complexed with double-stranded DNA at 3.0 A resolution shows bent DNA. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[9]  Samuel H. Wilson,et al.  Human Immunodeficiency Virus Type 1 Reverse Transcriptase , 1995, The Journal of Biological Chemistry.

[10]  Jianping Ding,et al.  Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. , 1994, Journal of molecular biology.

[11]  S. Sarafianos,et al.  Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[12]  C. Ehresmann,et al.  The Emergence of Different Resistance Mechanisms toward Nucleoside Inhibitors Is Explained by the Properties of the Wild Type HIV-1 Reverse Transcriptase* , 2001, The Journal of Biological Chemistry.

[13]  T. Steitz,et al.  Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. , 1992, Science.

[14]  R. Karlsson,et al.  Experimental design for kinetic analysis of protein-protein interactions with surface plasmon resonance biosensors. , 1997, Journal of immunological methods.

[15]  J. Tronchet,et al.  Nonnucleoside inhibitors of HIV-1 reverse transcriptase: from the biology of reverse transcription to molecular design. , 2003, Current topics in medicinal chemistry.

[16]  H. Buc,et al.  Structures of Complexes Formed by HIV-1 Reverse Transcriptase at a Termination Site of DNA Synthesis* , 2001, The Journal of Biological Chemistry.

[17]  D. I. Stuart,et al.  Crystal Structures of Zidovudine- or Lamivudine-Resistant Human Immunodeficiency Virus Type 1 Reverse Transcriptases Containing Mutations at Codons 41, 184, and 215 , 2002, Journal of Virology.

[18]  K. Sakaguchi,et al.  Mode Analysis of a Fatty Acid Molecule Binding to the N-terminal 8-kDa Domain of DNA Polymerase β , 1999, The Journal of Biological Chemistry.

[19]  J. Martínez-Irujo,et al.  Synergistic inhibition of HIV-1 reverse transcriptase by combinations of chain-terminating nucleotides. , 1997, Biochemistry.

[20]  A. D. Clark,et al.  Crystal structure of HIV‐1 reverse transcriptase in complex with a polypurine tract RNA:DNA , 2001, The EMBO journal.

[21]  P. V. von Hippel,et al.  Function and Assembly of the Bacteriophage T4 DNA Replication Complex , 2003, Journal of Biological Chemistry.

[22]  M. Fukushima,et al.  Differential inhibitory effects of various flavonoids on the activities of reverse transcriptase and cellular DNA and RNA polymerases. , 1990, European journal of biochemistry.

[23]  Michael A. Parniak,et al.  A Tight-Binding Mode of Inhibition Is Essential for Anti-Human Immunodeficiency Virus Type 1 Virucidal Activity of Nonnucleoside Reverse Transcriptase Inhibitors , 2002, Antimicrobial Agents and Chemotherapy.

[24]  K A Johnson,et al.  Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors , 1995, Science.

[25]  P. Schuck,et al.  Kinetics of ligand binding to receptor immobilized in a polymer matrix, as detected with an evanescent wave biosensor. I. A computer simulation of the influence of mass transport. , 1996, Biophysical journal.

[26]  R. S. Goody,et al.  Multiparameter single-molecule fluorescence spectroscopy reveals heterogeneity of HIV-1 reverse transcriptase:primer/template complexes , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[27]  L. Christensen Theoretical analysis of protein concentration determination using biosensor technology under conditions of partial mass transport limitation. , 1997, Analytical biochemistry.

[28]  M. Kruhøffer,et al.  Inhibition of human immunodeficiency virus 1 reverse transcriptase by 3'-azidothymidine triphosphate. , 1990, European journal of biochemistry.

[29]  K. Anderson,et al.  Mechanistic Studies to Understand the Progressive Development of Resistance in Human Immunodeficiency Virus Type 1 Reverse Transcriptase to Abacavir* , 2002, The Journal of Biological Chemistry.

[30]  D I Stuart,et al.  Crystal structures of HIV-1 reverse transcriptase in complex with carboxanilide derivatives. , 1998, Biochemistry.

[31]  F. Guengerich,et al.  Kinetics of Nucleotide Incorporation Opposite DNA Bulky Guanine N2 Adducts by Processive Bacteriophage T7 DNA Polymerase (Exonuclease–) and HIV-1 Reverse Transcriptase* , 2005, Journal of Biological Chemistry.

[32]  G. Deléage,et al.  Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. , 1995, Journal of molecular biology.

[33]  S. Goff,et al.  Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. , 2003, Journal of molecular biology.

[34]  R. Goody,et al.  Refined model for primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic analyses of primer/template binding and nucleotide incorporation events distinguish between different binding modes depending on the nature of the nucleic acid substrate. , 1999, Journal of molecular biology.

[35]  Mengsu Yang,et al.  Surface plasmon resonance study of DNA polymerases binding to template/primer DNA duplexes immobilized on supported lipid monolayers , 2000 .

[36]  Ivet Bahar,et al.  Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. , 2004, Current HIV research.

[37]  N. Nakamura,et al.  Flavanone and flavonol glycosides from the leaves of Thevetia peruviana and their HIV-1 reverse transcriptase and HIV-1 integrase inhibitory activities. , 2002, Chemical & pharmaceutical bulletin.

[38]  S. L. Le Grice,et al.  HIV-1 reverse transcriptase interaction with model RNA-DNA duplexes. , 2001, Analytical biochemistry.

[39]  William L. Jorgensen,et al.  Validation of a Model for the Complex of HIV-1 Reverse Transcriptase with Sustiva through Computation of Resistance Profiles , 2000 .

[40]  B. Canard,et al.  Enhanced Binding of Azidothymidine-resistant Human Immunodeficiency Virus 1 Reverse Transcriptase to the 3′-Azido-3′-deoxythymidine 5′-Monophosphate-terminated Primer* , 1998, The Journal of Biological Chemistry.

[41]  S. Sharma,et al.  Nucleotide-induced stable complex formation by HIV-1 reverse transcriptase. , 1997, Biochemistry.

[42]  Mengsu Yang,et al.  Kinetic study of various binding modes between human DNA polymerase beta and different DNA substrates by surface-plasmon-resonance biosensor. , 2002, The Biochemical journal.

[43]  A. Telesnitsky,et al.  Footprint analysis of replicating murine leukemia virus reverse transcriptase. , 1995, Science.

[44]  S. Goff,et al.  The effect of NNRTIs on HIV reverse transcriptase dimerization. , 2003, Current opinion in investigational drugs.

[45]  Stephen H. Hughes,et al.  Nonnucleoside Inhibitor Binding Affects the Interactions of the Fingers Subdomain of Human Immunodeficiency Virus Type 1 Reverse Transcriptase with DNA , 2004, Journal of Virology.

[46]  G L Verdine,et al.  Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. , 1998, Science.

[47]  Jiannis Ragoussis,et al.  Quantitative high-throughput analysis of transcription factor binding specificities. , 2004, Nucleic acids research.

[48]  K. Sakaguchi,et al.  Three-dimensional structural model analysis of the binding site of an inhibitor, nervonic acid, of both DNA polymerase beta and HIV-1 reverse transcriptase. , 2002, Journal of biochemistry.

[49]  A. D. Clark,et al.  Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: implications of conformational changes for polymerization and inhibition mechanisms. , 1996, Structure.

[50]  M. V. Van Regenmortel,et al.  Concentration measurement of unpurified proteins using biosensor technology under conditions of partial mass transport limitation. , 1997, Analytical biochemistry.

[51]  A. D. Clark,et al.  Structure and functional implications of the polymerase active site region in a complex of HIV-1 RT with a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A resolution. , 1998, Journal of molecular biology.

[52]  W A Hendrickson,et al.  Mechanistic implications from the structure of a catalytic fragment of Moloney murine leukemia virus reverse transcriptase. , 1995, Structure.

[53]  R. Goody,et al.  Kinetics of interaction of HIV reverse transcriptase with primer/template. , 1993, Biochemistry.

[54]  R. Goody,et al.  Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[55]  G. Maga,et al.  Selective Interaction of the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Nonnucleoside Inhibitor Efavirenz and Its Thio-Substituted Analog with Different Enzyme-Substrate Complexes , 2000, Antimicrobial Agents and Chemotherapy.

[56]  S. Doublié,et al.  The Motif D Loop of Human Immunodeficiency Virus Type 1 Reverse Transcriptase Is Critical for Nucleoside 5′-Triphosphate Selectivity* , 1999, The Journal of Biological Chemistry.

[57]  Christopher M. Bailey,et al.  Defining a Molecular Mechanism of Synergy between Nucleoside and Nonnucleoside AIDS Drugs* , 2004, Journal of Biological Chemistry.

[58]  A. D. Clark,et al.  Structures of HIV‐1 reverse transcriptase with pre‐ and post‐translocation AZTMP‐terminated DNA , 2002, The EMBO journal.

[59]  R W Glaser,et al.  Antigen-antibody binding and mass transport by convection and diffusion to a surface: a two-dimensional computer model of binding and dissociation kinetics. , 1993, Analytical biochemistry.

[60]  K. Sakaguchi,et al.  The inhibitory action of fatty acids on DNA polymerase beta. , 1997, Biochimica et biophysica acta.

[61]  D J Newman,et al.  Natural product-based anti-HIV drug discovery and development facilitated by the NCI developmental therapeutics program. , 2001, Journal of natural products.

[62]  Erik De Clercq Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection , 1999 .

[63]  J Luo,et al.  Antibody-antigen interactions measured by surface plasmon resonance: global fitting of numerical integration algorithms. , 2001, Journal of biochemistry.

[64]  Xiaomin Luo,et al.  Steered molecular dynamics simulation on the binding of NNRTI to HIV-1 RT. , 2003, Biophysical journal.